-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$35.0083.34% Upside
Rapport Therapeutics, Inc. Common Stock Frequently Asked Questions
-
What analysts cover Rapport Therapeutics, Inc. Common Stock?
Rapport Therapeutics, Inc. Common Stock has been rated by research analysts at Jefferies, Stifel Nicolaus in the past 90 days.